![[CysCys21] Atrial Natriuretic Factor (3-28), Rat CAS NO.90984-99-9](https://images.cnmqh.com/images/a10134/786afb1641568469e8b5b3ebe23db092-20260130022200.webp "[CysCys21] Atrial Natriuretic Factor (3-28), Rat CAS NO.90984-99-9")
[CysCys21] Atrial Natriuretic Factor (3-28), Rat CAS NO.90984-99-9
[CysCys21] Atrial Natriuretic Factor (3-28), Rat CAS NO.90984-99-9
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | [CysCys21] Atrial Natriuretic Factor (3-28), Rat |
| CAS NO. | 90984-99-9 |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C119H189N43O36S2 |
| Molecular Weight | 2862.2g/mol |
| Purity (RP-HPLC) | ≥ 95.0% |
| Solubility | Soluble in water, phosphate‑buffered saline (PBS), or dilute acetic acid (e.g., 0.1 % v/v). For best results, first dissolve in a small volume of 0.1 % acetic acid or sterile water to prepare a 0.1‑1.0 mg/mL stock solution, then dilute with assay buffer |
| Endotoxin | < 1.0 EU/mg |
| Biological Activity | This analog of rat ANF(3‑28) retains the ability to bind to natriuretic peptide receptors (primarily NPR‑A) and stimulate guanylyl cyclase activity, leading to increased intracellular cGMP levels. The Cys‑Cys substitution at position 21 may be designed to introduce a reactive thiol pair for conjugation, labeling, or structural studies. Bioactivity should be confirmed by cGMP accumulation or vascular relaxation assays. |
| Storage Conditions | Lyophilized powder: Store desiccated at –20 °C or below, protected from light. Reconstituted solution: Aliquot and store at ≤ –20 °C; avoid repeated freeze‑thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
The peptide functions as a ligand for natriuretic peptide receptors, primarily NPR‑A, by binding to the extracellular domain through its conserved disulfide-constrained core structure. This interaction activates membrane-bound guanylyl cyclase, increasing intracellular cyclic GMP (cGMP) levels and subsequently activating cGMP-dependent protein kinases. The resulting signaling cascade promotes vasodilation, natriuresis, and diuresis, while inhibiting the renin–angiotensin–aldosterone system. The [CysCys²¹] modification does not disrupt this canonical pathway but provides a reactive handle for covalent conjugation without compromising receptor engagement in appropriate assay systems.
2.PRODUCT INDICATIONS
This modified ANF analog is indicated exclusively for research use in preclinical studies of natriuretic peptide receptor biology and probe development. It is employed as a scaffold for site-specific conjugation to fluorophores, biotin, or other tags to generate labeled ligands for receptor imaging, flow cytometry, immunohistochemistry, and pull-down assays. The unlabeled peptide serves as a cold competitor in displacement studies and can be used in functional assays to assess cGMP accumulation and vascular responses. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.
3.CLINICAL EFFICACY OF PRODUCT
As a research reagent and conjugation scaffold, [CysCys²¹] Atrial Natriuretic Factor (3‑28), Rat has no established clinical efficacy for therapeutic use. The product has not undergone clinical development, regulatory approval, or safety evaluation for any medical indication. While it contributes to the development of molecular probes and tools for studying cardiovascular and renal diseases, its utility is confined to laboratory research. There are no proven clinical benefits or safety data supporting its use in human patients.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
Nov 05, 26
Global Market Analysis and Oxandrolone 50mg Price Guide
For B2B pharmaceutical buyers and researchers, understanding the oxandrolone 50mg price involves analyzing more than just a numerical value; it requires a comprehensive look at API purity, synthesis methods, and global supply chain stability. As a specialized anabolic steroid derivative, the cost is heavily influenced by the quality of raw materials and the rigor of the laboratory testing involved in the production process. This article explores the economic and technical variables that dictate market pricing for this specific compound. In the context of the global API market, pricing volatility is often tied to regulatory shifts in key manufacturing hubs
Nov 04, 26
How to Select High Purity Alisol C CAS 30489271 for Laboratory Research
High Purity Alisol C CAS 30489271 is suited to laboratories using Alisol C as a triterpenoid reference standard in metabolic, hepatology, pharmacology, HPLC/MS, botanical-extract, or selected cell-line research. We explain the application fit and the identity, purity, physical form, solvent, endotoxin, storage, quantity, and batch-record checks to make before ordering.
Nov 02, 26
Reliable Oxandrolone Supplier for High Purity Pharmaceutical APIs
When sourcing high-purity pharmaceutical ingredients for endocrine or cardiovascular research, the reliability of the supply chain is as critical as the chemical purity itself. For laboratories and manufacturers seeking a dependable oxandrolone supplier, the focus must extend beyond simple certificates of analysis to encompass consistent batch-to-batch stability and strict adherence to GMP standards. Whether the requirement is for small-scale pilot studies or large-scale industrial production, the ability to trace materials from raw synthesis to final lyophilized powder ensures the integrity of the resulting clinical or research data.